IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK)

Innate Pharma

Status and phase: Active, not recruiting; Phase 2

Conditions: Lymphoma, T-Cell; Mycosis Fungoides/Sezary Syndrome; Lymphoma, T-Cell, Cutaneous

Treatments: Biological: IPH4102

Study type: Interventional

Funder types: Industry

Identifiers

NCT03902184

IPH4102-201

2023-507777-18-00 (EU Trial (CTIS) Number)

2018-003969-33 (EudraCT Number)

Details and patient eligibility

About

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

Enrollment: 170 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

SS patients (Cohort 1):

1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies;

2. Prior treatment with mogamulizumab;

3. Patients should have blood stage B2 at screening based on central evaluation by flow cytometry;

4. Feasibility of obtaining at least one skin biopsy at screening;

   MF patients (Cohorts 2 and All comers):

5. Relapsed and/or refractory stage IB, IIA, IIB, III, IV MF;

6. Only for Cohort 2: KIR3DL2 expression in at least one expressing skin lesion based on central evaluation by IHC;

7. Patients should have received at least two prior systemic therapies;

8. Feasibility of obtaining at least one skin biopsy at screening;

   Additional inclusion criteria applicable to all cohorts:

9. Male or Female, at least 18 years of age;

10. ECOG performance status ≤2;

11. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy and the first dose of IPH4102;

12. Patients should have recovered from all non-hematological adverse events related to prior therapy to ≤ grade 1 except for alopecia;

13. Adequate baseline laboratory data:

    Hematology:

    • Hemoglobin >9 g/dL,
    • Absolute neutrophil count (ANC) ≥1,500/µL,
    • Platelets ≥100,000/µL,

    Biochemistry:

    • Bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with Gilbert's disease,
    • Serum creatinine ≤1.5 X ULN,
    • Creatinine clearance ≥30 mL/min, calculated with the Cockcroft & Gault formula,
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 X ULN;

14. Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12 months and capable to become pregnant. They must have a negative serum beta-HCG pregnancy test result within seven days from start of treatment;

15. Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug;

16. Signed informed consent form prior to any protocol-specific procedures

Exclusion Criteria:

1. Patients with evidence of large cell transformation (LCT) based on central histologic evaluation at screening;

2. Receipt of live vaccines within 4 weeks prior to treatment;

3. Central nervous system (CNS) lymphoma involvement;

4. Prior administration of IPH4102;

5. Concurrent enrollment in another clinical trial, unless it is an observational (non - interventional) clinical study or the follow-up period of an interventional study;

6. Autologous stem cell transplantation less than 3 months prior to enrollment;

7. Prior allogenic transplantation;

8. Patients who have undergone major surgery ≤ 4 weeks prior to study entry;

9. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection;

10. Patients who have Hepatitis B Virus infection determined as HBsAg positive and / or Hepatitis C Virus infection determined as detection of HCV RNA in serum or plasma by a sensitive quantitative molecular method;

11. Known or tested positive for human immunodeficiency virus (HIV);

12. Patients with a history of other malignancies during the past five years apart from the disease subject of this study. The following are exempt from the five-year limit: non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer, biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or cervical carcinoma in situ

13. Pregnant or breastfeeding women;

14. Known clinically significant cardiovascular disease or condition, including:

    • Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) Functional Classification;
    • Any uncontrolled arrhythmia (per the investigator's discretion);
    • Uncontrolled hypertension (per the investigator's discretion).

15. Patients with autoimmune disease on systemic immunosuppressive treatment;

16. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol;

17. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

170 participants in 4 patient groups

Cohort 1: Relapsed/refractory Sezary Syndrome

Experimental group

Description:

IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.

Treatment:

Biological: IPH4102

Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing

Experimental group

Description:

IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.

Treatment:

Biological: IPH4102

Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed)

Experimental group

Description:

IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.

Treatment:

Biological: IPH4102

Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressing

Experimental group

Description:

IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.

Treatment:

Biological: IPH4102